VIKING GLOBAL INVESTORS LP 13D and 13G filings for Inhibrx Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-06-03 5:56 pm Sale |
2024-05-30 | 13G | Inhibrx Biosciences, Inc. INBX |
VIKING GLOBAL INVESTORS LP | 0 0.000% |
-7,150,826 (Position Closed) |
Filing |
| 2024-02-14 10:00 am Purchase |
2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
VIKING GLOBAL INVESTORS LP | 7,150,826 15.100% |
511,627 (+7.71%) |
Filing |
| 2023-02-14 1:18 pm Purchase |
2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
VIKING GLOBAL INVESTORS LP | 6,639,199 15.200% |
1,333,333 (+25.13%) |
Filing |
| 2022-02-14 5:02 pm Unchanged |
2021-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
VIKING GLOBAL INVESTORS LP | 5,305,866 14.000% |
0 (Unchanged) |
Filing |
| 2021-02-12 7:43 pm Purchase |
2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
VIKING GLOBAL INVESTORS LP | 5,305,866 14.100% |
180,219 (+3.52%) |
Filing |
| 2020-08-31 4:51 pm Purchase |
2020-08-21 | 13G | Inhibrx Biosciences, Inc. INBX |
VIKING GLOBAL INVESTORS LP | 5,125,647 13.600% |
5,125,647 (New Position) |
Filing |